TME Pharma N.V.

ALTME

NL0015000YE1

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-02-16 am EST			5-day change	1st Jan Change
0.0752 ^EUR	-6.00%		-1.70%	+15.34%

Jan. 05	TME Pharma N.V. Provides Update on Its Activities	CI
Nov. 17	TME Pharma N.V. Announces Extension of Certain Bond Agreements	CI

TME Pharma Lands Bonds Extension Approval From 29% Holders

Published on 11/17/2025 at 05:45 am EST

MT Newswires

Latest news about TME Pharma N.V.

Jan. 05	TME Pharma N.V. Provides Update on Its Activities	CI
Nov. 17	TME Pharma N.V. Announces Extension of Certain Bond Agreements	CI
Nov. 17	TME Pharma Lands Bonds Extension Approval From 29% Holders	MT
25-10-29	TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-27	TME Pharma N.V. announced that it has received ?0.5 million in funding	CI
25-08-25	TME Pharma Plans Bond Issue to Boost Financial Capacity	MT
25-08-24	TME Pharma N.V. announced that it expects to receive ?0.5 million in funding	CI
25-06-25	TME Pharma N.V. Approves Appointment of Diede Van Den Ouden as Chief Executive Officer	CI
25-06-25	Tme Pharma N.V. Appoints Diede Mink Van Den Ouden as Sole Member of the Board of Directors	CI
25-06-18	TME Pharma N.V. Announces Successful Next Step in Its NOX-E36 Ophthalmology Strategy with Signature of Option Framework Agreement with Singapore Eye Research Institute	CI
25-06-18	TME Pharma, Seri Sign New Deal for Clinical Development of Ophthalmic Disease Molecule	MT
25-06-18	TME Pharma N.V. and Singapore Eye Research Institute Sign Option Framework Agreement	CI
25-06-18	Singapore Eye Research Institute Signs Ophthalmology Framework Agreement with German Firm	MT
25-05-27	TME Pharma N.V. announced that it has received ?1.7 million in funding	CI
25-05-26	Invest Securities Upgrades TME Pharma to Buy Rating, Trims PT	MT

TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.

Employees

Sector

Biotechnology & Medical Research

Calendar

Apr. 28 - Q4 2025 Earnings Release (Projected)

More about the company